Order Article Reprints

Nishimura T, Fujimoto H, Okano T, Naito M, Tsuji C, Iwanaka S, Sakakura Y, Yasuma T, D’Alessandro-Gabazza CN, Oomoto Y, et al. Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice? Cancers. 2022; 14(12):2970. https://doi.org/10.3390/cancers14122970

Nishimura, Tadashi, Hajime Fujimoto, Tomohito Okano, Masahiro Naito, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Taro Yasuma, Corina N. D’Alessandro-Gabazza, Yasuhiro Oomoto, and et al. 2022. "Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?" Cancers 14, no. 12: 2970. https://doi.org/10.3390/cancers14122970

Nishimura, T., Fujimoto, H., Okano, T., Naito, M., Tsuji, C., Iwanaka, S., Sakakura, Y., Yasuma, T., D’Alessandro-Gabazza, C. N., Oomoto, Y., Gabazza, E. C., Kobayashi, T., & Ibata, H. (2022). Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice? Cancers, 14(12), 2970. https://doi.org/10.3390/cancers14122970